MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$5.10
+0.47 (+10.15%)
Financial Highlights (FY 2026)
Revenue
856.04M
Net Income
-379,896,898
Gross Margin
69.9%
Profit Margin
-44.4%
Rev Growth
+6.7%
D/E Ratio
0.33
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | 31.6% | 31.6% |
| Operating Margin | -47.0% | -42.3% | -16.4% | -19.6% |
| Profit Margin | -44.4% | -42.2% | -21.1% | -16.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 856.04M | 802.14M | 74.53M | 73.26M |
| Gross Profit | 598.63M | 560.94M | 23.57M | 23.17M |
| Operating Income | -401,997,279 | -339,015,696 | -12,223,352 | -14,366,935 |
| Net Income | -379,896,898 | -320,377,818 | -15,758,896 | -11,828,489 |
| Gross Margin | 69.9% | 69.9% | 31.6% | 31.6% |
| Operating Margin | -47.0% | -42.3% | -16.4% | -19.6% |
| Profit Margin | -44.4% | -42.2% | -21.1% | -16.2% |
| Rev Growth | +6.7% | +6.7% | +5.3% | -4.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 52.69M | 52.69M | 122.72M | 106.53M |
| Total Equity | 161.71M | 161.71M | 215.66M | 214.57M |
| D/E Ratio | 0.33 | 0.33 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -346,256,688 | -308,230,747 | -16,042,014 | -17,865,875 |
| Free Cash Flow | — | — | -13,316,178 | -13,196,312 |